Tivozanib Active Not Recruiting Phase 3 Trials for Renal Cell Adenocarcinoma Treatment

IndicationsStatusPurposePhase
Active Not RecruitingTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT02627963A Study to Compare Tivozanib Hydrochloride to Sorafenib in Subjects With Refractory Advanced RCC